In discussion: manufacturing beyond serialization compliance

18–02–2019
1 min to read

Counterfeit medicines pose a huge threat to patient safety, which has been the primary driver behind new global serialization regulations, such as the US Drug Supply Chain Safety Act (DSCSA) and the EU Falsified Medicines Directive (FMD). However, these initiatives can also add further value to the pharmaceutical supply chain.

In this article with Pharmaceutical Processing, Dexter Tjoa, Director Corporate Strategy at Tjoapack discusses the potential benefits of implementing aggregation and single unit dose track & trace solutions from an early stage. And, how exploring value beyond compliance will ensure companies make the most out of their investment. Read the full article here: https://bit.ly/2EdHP6p

By Tjoapack